Cerdulatinib

May 05, 2020

Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion

May 01, 2020

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Apr 23, 2020

Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020

Apr 01, 2020

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Feb 24, 2020

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Dec 23, 2019

Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020

Dec 08, 2019

Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies

Nov 06, 2019

Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting

Nov 01, 2019

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aug 22, 2019

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Jul 17, 2019

Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019

Jun 19, 2019

Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma